Health Canada
Santé Canada

STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: Eperisone

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

Controlled	☐
Not Controlled	X

under the schedules of the *Controlled Drugs and Substances Act* (CDSA) for the following reason(s):

- The substance is not structurally similar to any of those listed in the CDSA.

Prepared by: _____ Date: _____
Vincent Marleau

Verified by: _____ Date: _____
Mark Kozlowski

Approved by: _____ Date: _____
DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES

This status was requested by: Yasir Hussain, Border Integrity Unit

Drug Status Report

Drug: Eperisone

Drug Name Status: Eperisone is the common name.

Chemical Name: 1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)-

Other Names: (+-)-Eperisone; 1-(4-Ethylphenyl)-2-methyl-3-(1-piperidinyl)-1-propanone; 4'-Ethyl-2-methyl-3-piperidinopropiophenone.

Chemical structure:



Molecular Formula: $C_{17}H_{25}NO$ **CAS-RN:** 64840-90-0**(**56839-43-1 - HCl)

Pharmacological class / Application: Antispasmodic

International status:

US: Eperisone is not listed specifically in the Schedules to the US *Controlled Substances Act* and is not mentioned anywhere on the DEA website.

United Nations: The substance is not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances under International Control.

Canadian Status: Eperisone is not listed in the CDSA. The substance is a muscle[1] and is marketed under the brand name Myonal (eperisone hydrochloride), which is sold in Japan, India and Bangladesh. Eperisone is not structurally similar to any of the substances listed in the CDSA.

Recommendation: Eperisone is not included in the Schedules to the CDSA and is not a controlled substance.

Date: August 20th, 2012.

[1] Bresolin, N., Zucca, C., & Pecori, A. (2009). Efficacy and tolerability of eperisone and baclofen in spastic palsy: A double-blind randomized trial. Advances in Therapy, **26(5):** 563-573.